Capstone Investment Advisors’s Ibere Pharmaceuticals IBER Stock Holding History

Capstone Investment Advisors’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-25,000	Closed	-$252K	–	1801
2022 Q4	$252K	Hold	25,000	–	–	﹤0.01%	1265
2022 Q3	$248K	Hold	25,000	–	–	﹤0.01%	1429
2022 Q2	$245K	Hold	25,000	–	–	﹤0.01%	1381
2022 Q1	$245K	Hold	25,000	–	–	﹤0.01%	1635
2021 Q4	$243K	Hold	25,000	–	–	﹤0.01%	1557
2021 Q3	$242K	Hold	25,000	–	–	﹤0.01%	1671
2021 Q2	$242K	Buy	+25,000	New	+$243K	﹤0.01%	1484

Capstone Investment Advisors's IBER Position: Q1 2023 in Review

Capstone Investment Advisors sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 25,000 shares — an estimated $252K sold.

Capstone Investment Advisors first reported a position in IBER in Q2 2021 and held it in 7 quarters. The position peaked at $252K in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

Capstone Investment Advisors reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Capstone Investment Advisors sold 25,000 Ibere Pharmaceuticals shares in Q1 2023, an estimated $252K.
Capstone Investment Advisors first reported a position in Ibere Pharmaceuticals in Q2 2021 and held it in 7 quarters.
Capstone Investment Advisors's Ibere Pharmaceuticals position peaked at $252K in Q4 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Capstone Investment Advisors's 13F filing for Q1 2023, filed 9 May 2023.